HIV drug resistance tests are here to stay

Current Opinion in Infectious Diseases

Volumn 12, Issue 1, 1999, Pages 27-32

  Boucher, Charles A B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DATA ANALYSIS; DATA BASE; DRUG CHOICE; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; METHODOLOGY; REVIEW; VERTICAL TRANSMISSION;

EID: 0032971190     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199902000-00005     Document Type: Review

References (15)

1. Hirsch MS, Conway B, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM et al. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. J Am Med Assoc 1998; 279:1984-1991.
2. U.S Dept. Of Health and Human Services. Public health service guidelines for the management of health-care worker exposure to HIV and recommendations for postexposure prophylaxis Mortality and Morbidity Weekly Reports 1998, 47:1-28.
3. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors [see comments]. N Engl J Med 1998, 339:307-311.
4. Nijuis M, Schuurman R, de Jong D, van Leeuwen R, Lange JMA, Danner SA et al. Lamivudine resistant HIV-1 variants (M184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo J Infect Dis 1997; 176:398-405.
5. Brun-Vézinet F, Boucher CAB, Loveday C, et al., and the DELTA virology working group. HIV-1 viral load, phenotype and resistance in a subset of drug-naive participants from the DELTA trial. Lancet 1997; 350:983-990.
6. Leigh Brown AJ, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Baseline sequence clusters predict response to combination therapy in ACTG 241. International Medical Press 1998; Abstract #50:35 Abstract
7. Zolopa AR, Shafer RW, Warford A, Montoya JG, Katzenstein D, Merigan TC. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. International Medical Press 1998; Abstract #54:37 Abstract
8. Harrigan PR, Montaner JS, Hogg RS, Yip B, Hertogs K, Pauwels R, Bloor S, Larder B. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. International Medical Press 1998; Abstract #55:38 Abstract.
9. Deeks SG, Parkin N, Petropoulos CJ, Grant RM, Volberding PA, Whitcomb J, Tian H, Wrin T, Limoli K, Drews B, Warmerdam M, Hellmann NS. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy International Medical Press 1998; Abstract #53:36 Abstract.
10. Patick AK, Zhang M, Hertogs K, Griffiths L, Mazabel E, Pauwels R, Becker M Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program International Medical Press 1998; Abstract 57:39 Abstract
11. Lanier R, Danehower S, Daluge S, Cutrell A, Tisdale M, Pearce G, Spreen B, Lafon S, Kemp SD, Bloor S, Larder BA. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). International Medical Press 1998; Abstract #52.36 Abstract
12. Durant J, Clevenbergh P, Halfen P, Delguidice P, Porsin S, Simoner P, Montagne N, Dohin E, Dellamonica P. Can HIV genotype determination be useful for individualized adaptation of antiretroviral therapy: the VIRADAPT french study. AIDS 1998; 12 S16 Abstract.
13. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs Antimicrob Agents Chemother 1998; 42:269-276.
14. Nijhuis M, Schuurman R, Boucher CAB. Homologous recombination for rapid phenotyping of HIV. Curr Opin Infect Dis 1997; 10:475-479.
15. Schuurman R. State of the art of genotypic HIV-1 drug resistance. Curr Opin Infect Dis 1997; 10:480-484.